BMS, Infinity form collaboration to evaluate Opdivo + IPI-549 in urothelial cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. and Infinity Pharmaceuticals Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Infinity’s IPI-549 in patients with advanced urothelial cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login